PPA
CLDX icon

Parametric Portfolio Associates’s Celldex Therapeutics CLDX Stock Holding History

Parametric Portfolio Associates’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$292K Sell
8,568
-7,716
-47% -$247K ﹤0.01% 3292
2021
Q4 		$629K Sell
16,284
-30,124
-65% -$1.31M ﹤0.01% 2963
2021
Q3 		$2.51M Buy
46,408
+35,654
+332% +$1.67M ﹤0.01% 2312
2021
Q2 		$360K Sell
10,754
-486
-4% -$13.3K ﹤0.01% 3205
2021
Q1 		$232K Buy
+11,240
New +$258K ﹤0.01% 3819
2019
Q4 		– Sell
-10,657
Closed -$23K – 3965
2019
Q3 		$23K Buy
+10,657
New +$24.7K ﹤0.01% 3924
2018
Q2 		– Sell
-3,733
Closed -$130K – 3888
2018
Q1 		$130K Buy
3,733
+354
+10% +$13.7K ﹤0.01% 3825
2017
Q4 		$144K Buy
3,379
+1,542
+84% +$66.1K ﹤0.01% 3795
2017
Q3 		$79K Buy
1,837
+1,123
+157% +$42.1K ﹤0.01% 3971
2017
Q2 		$26K Sell
714
-3,678
-84% -$163K ﹤0.01% 3978
2017
Q1 		$238K Buy
4,392
+94
+2% +$4.89K ﹤0.01% 3535
2016
Q4 		$228K Buy
4,298
+3,162
+278% +$180K ﹤0.01% 3546
2016
Q3 		$69K Sell
1,136
-3,894
-77% -$243K ﹤0.01% 3712
2016
Q2 		$331K Buy
5,030
+3,735
+288% +$237K ﹤0.01% 3406
2016
Q1 		$73K Sell
1,295
-425
-25% -$47.8K ﹤0.01% 3900
2015
Q4 		$404K Sell
1,720
-112
-6% -$24.4K ﹤0.01% 3391
2015
Q3 		$290K Sell
1,832
-1,556
-46% -$440K ﹤0.01% 2980
2015
Q2 		$1.28M Sell
3,388
-151
-4% -$60K ﹤0.01% 2601
2015
Q1 		$1.48M Buy
3,539
+157
+5% +$56.2K ﹤0.01% 2482
2014
Q4 		$926K Buy
3,382
+792
+31% +$197K ﹤0.01% 2841
2014
Q3 		$503K Buy
2,590
+1,220
+89% +$266K ﹤0.01% 3201
2014
Q2 		$335K Buy
1,370
+104
+8% +$23.5K ﹤0.01% 3456
2014
Q1 		$336K Sell
1,266
-223
-15% -$85.4K ﹤0.01% 3381
2013
Q4 		$541K Buy
1,489
+593
+66% +$228K ﹤0.01% 3112
2013
Q3 		$476K Sell
896
-20
-2% -$6.86K ﹤0.01% 3128
2013
Q2 		$215K Buy
+916
New +$180K ﹤0.01% 3441

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Parametric Portfolio Associates's CLDX Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Celldex Therapeutics (CLDX) stake by 47% in Q1 2022, selling an estimated $247K and leaving 8,568 shares worth $292K. The position accounts for ﹤0.01% of the portfolio, ranked #3292.

Parametric Portfolio Associates first reported a position in CLDX in Q2 2013 and has held it in 26 quarters since. The position peaked at $2.51M in Q3 2021. 168 funds tracked by Wall St. Rank hold CLDX as of Q1 2022.

  • Parametric Portfolio Associates held 8,568 shares of Celldex Therapeutics worth $292K as of Q1 2022.
  • Parametric Portfolio Associates sold 7,716 Celldex Therapeutics shares in Q1 2022, an estimated $247K.
  • Celldex Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3292 holding.
  • Parametric Portfolio Associates first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 26 quarters since.
  • Parametric Portfolio Associates's Celldex Therapeutics position peaked at $2.51M in Q3 2021.
  • 168 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.